Citigroup’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-467,686
| Closed | -$33.7M | – | 6323 |
|
|
2025
Q4 | $33.7M | Buy |
467,686
+438,359
| +1,495% | +$28.3M | 0.01% | 815 |
|
|
2025
Q3 | $1.28M | Sell |
29,327
-260,527
| -90% | -$10.5M | ﹤0.01% | 3001 |
|
|
2025
Q2 | $8.23M | Sell |
289,854
-87,425
| -23% | -$2.61M | ﹤0.01% | 1514 |
|
|
2025
Q1 | $11.1M | Buy |
377,279
+187,325
| +99% | +$5.83M | 0.01% | 1301 |
|
|
2024
Q4 | $5.52M | Buy |
189,954
+78,272
| +70% | +$3.27M | ﹤0.01% | 1854 |
|
|
2024
Q3 | $5.13M | Buy |
111,682
+67,761
| +154% | +$2.94M | ﹤0.01% | 1821 |
|
|
2024
Q2 | $1.79M | Sell |
43,921
-191,944
| -81% | -$5.51M | ﹤0.01% | 2438 |
|
|
2024
Q1 | $6.02M | Buy |
235,865
+150,263
| +176% | +$2.35M | ﹤0.01% | 1581 |
|
|
2023
Q4 | $775K | Sell |
85,602
-56,926
| -40% | -$381K | ﹤0.01% | 3056 |
|
|
2023
Q3 | $909K | Sell |
142,528
-36,204
| -20% | -$312K | ﹤0.01% | 2597 |
|
|
2023
Q2 | $1.98M | Sell |
178,732
-75,839
| -30% | -$951K | ﹤0.01% | 2225 |
|
|
2023
Q1 | $3.91M | Buy |
254,571
+139,726
| +122% | +$3.07M | ﹤0.01% | 1627 |
|
|
2022
Q4 | $2.55M | Buy |
114,845
+46,684
| +68% | +$696K | ﹤0.01% | 1859 |
|
|
2022
Q3 | $1.11M | Buy |
68,161
+11,916
| +21% | +$228K | ﹤0.01% | 2633 |
|
|
2022
Q2 | $817K | Buy |
56,245
+28,583
| +103% | +$425K | ﹤0.01% | 2838 |
|
|
2022
Q1 | $511K | Sell |
27,662
-46,079
| -62% | -$783K | ﹤0.01% | 3482 |
|
|
2021
Q4 | $1.75M | Buy |
73,741
+14,596
| +25% | +$349K | ﹤0.01% | 2732 |
|
|
2021
Q3 | $1.46M | Sell |
59,145
-45,482
| -43% | -$989K | ﹤0.01% | 2790 |
|
|
2021
Q2 | $2.58M | Buy |
104,627
+28,119
| +37% | +$654K | ﹤0.01% | 2462 |
|
|
2021
Q1 | $1.67M | Buy |
76,508
+71,383
| +1,393% | +$1.75M | ﹤0.01% | 2611 |
|
|
2020
Q4 | $131K | Buy |
5,125
+4,322
| +538% | +$126K | ﹤0.01% | 5318 |
|
|
2020
Q3 | $23K | Buy |
+803
| New | +$23.2K | ﹤0.01% | 6098 |
|
Other funds holding RNAM
Citigroup's RNAM Position: Q1 2026 in Review
Citigroup sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 467,686 shares — an estimated $33.7M sold.
Citigroup first reported a position in RNAM in Q3 2020 and held it in 22 quarters. The position peaked at $33.7M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Citigroup reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Citigroup sold 467,686 Avidity Biosciences shares in Q1 2026, an estimated $33.7M.
- Citigroup first reported a position in Avidity Biosciences in Q3 2020 and held it in 22 quarters.
- Citigroup's Avidity Biosciences position peaked at $33.7M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.